BAY1830839   Click here for help

GtoPdb Ligand ID: 13101

Synonyms: BAY-1830839 | example 11 [WO2016083433A1] [2]
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: BAY1830839 is a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor [1]. It was developed for immunomodulatory potential. BAY1830839 is a structural analogue of zabedosertib (BAY1834845). Pharmacokinetics support oral administration.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 3
Rotatable bonds 8
Topological polar surface area 97.52
Molecular weight 450.45
XLogP 2.03
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC(C)(CCN1C=C2C=C(C(=CC2=N1)C(C)(C)O)NC(=O)C3=CC=CC(=N3)C(F)(F)F)O
Isomeric SMILES CC(C)(O)CCN1C=C2C=C(NC(=O)C=3C=CC=C(N3)C(F)(F)F)C(=CC2=N1)C(C)(C)O
InChI InChI=1S/C22H25F3N4O3/c1-20(2,31)8-9-29-12-13-10-17(14(21(3,4)32)11-16(13)28-29)27-19(30)15-6-5-7-18(26-15)22(23,24)25/h5-7,10-12,31-32H,8-9H2,1-4H3,(H,27,30)
InChI Key NWFPCWIBSBZRGV-UHFFFAOYSA-N
References
1. Bothe U, Günther J, Nubbemeyer R, Siebeneicher H, Ring S, Bömer U, Peters M, Rausch A, Denner K, Himmel H et al.. (2024)
Discovery of IRAK4 Inhibitors BAY1834845 (Zabedosertib) and BAY1830839.
J Med Chem, 67 (2): 1225-1242. [PMID:38228402]
2. Bothe U, Siebenreicher H, Schmidt N, Nubbemeyer R,Bomer U, Gunther J, Steuber H, Lange M, Stegmann C, Sutter A, Rausch A. (2016)
New substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs.
Patent number: WO2016083433A1. Assignee: Bayer Pharma. Priority date: 26/11/2014. Publication date: 02/02/2016.